Eudald Felip

11PUBLICATIONS
42CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer diagnosisChiropractic
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 08, 2025
Immune-based transcriptomic signature predicts CDK4/6 inhibitor efficacy in HR+/HER2- breast cancer.

Eudald Felip, Edurne Garcia-Vidal, Sara Cabrero-de Las Heras

|Nov 27, 2024
Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.

Iris Teruel, Eva Castellà, Sabela Recalde

|Jun 28, 2023
Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer.

Laura Pons, Laura Hernández, Aintzane Urbizu

|Jan 08, 2023
Immune Response and Effects of COVID-19 Vaccination in Patients with Lung Cancer-COVID Lung Vaccine Study.

Ainhoa Hernandez, Marc Boigues, Eudald Felip

|Dec 10, 2022
Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS-CoV-2 mRNA-1237 vaccine in patients with solid tumors.

Eudald Felip, Edwards Pradenas, Margarita Romeo

|Jul 27, 2022
Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer.

Angelica Ferrando-Díez, Eudald Felip, Anna Pous

Pageof 2

Frequent Collaborators

5 joint publications

Mireia Margelí

3 joint publications

Iris Teruel

3 joint publications

Anna Martínez-Cardús

2 joint publications

Ifeanyi Jude Ezeonwumelu